Bowie Capital Management LLC Makes New $24.32 Million Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• Bowie Capital Management initiated a $24.32 million position in Thermo Fisher Scientific during the second quarter, purchasing 48,517 shares. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $619.41; several firms recently raised their targets.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in adjusted EPS and $11.99 billion in revenue, while revenue increased 10.5% year over year. The company also announced a quarterly dividend of $0.47 per share.

Bowie Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 48,517 shares of the medical research company's stock, valued at approximately $24,324,000. Thermo Fisher Scientific accounts for about 1.0% of Bowie Capital Management LLC's portfolio, making the stock its 22nd largest position.

Several other institutional investors have also recently bought and sold shares of TMO. Allworth Financial LP bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $12,200,000. Greenspring Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $277,000. Silvant Capital Management LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $2,126,000. LaSalle St. Investment Advisors LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $416,000. Finally, Ceredex Value Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $25,880,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TMO shares. Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a report on Friday, July 24th. Piper Sandler upped their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research note on Monday, July 27th. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 11,440 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 63,493 shares of company stock worth $37,657,681. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $629.02 on Friday. The stock has a 50 day moving average price of $542.53 and a 200 day moving average price of $509.70. The firm has a market capitalization of $232.58 billion, a P/E ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business's revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source